新辅助化疗后残留 TNBC 的卡培他滨辅助化疗与序贯化疗:一项多中心比较研究。

IF 6.4 1区 医学 Q1 ONCOLOGY
Nalee Kim, Su Ssan Kim, Won Kyung Cho, Won Park, Ji Hyun Chang, Yong Bae Kim, Ah Ram Chang, Tae Hyun Kim, Jongmoo Park, Jin Hee Kim, Kyubo Kim, Yu Jin Lim, Tae Gyu Kim, Jin Hwa Choi, Jeanny Kwon, Sungmin Kim, Kyung Hwan Shin, Haeyoung Kim
{"title":"新辅助化疗后残留 TNBC 的卡培他滨辅助化疗与序贯化疗:一项多中心比较研究。","authors":"Nalee Kim, Su Ssan Kim, Won Kyung Cho, Won Park, Ji Hyun Chang, Yong Bae Kim, Ah Ram Chang, Tae Hyun Kim, Jongmoo Park, Jin Hee Kim, Kyubo Kim, Yu Jin Lim, Tae Gyu Kim, Jin Hwa Choi, Jeanny Kwon, Sungmin Kim, Kyung Hwan Shin, Haeyoung Kim","doi":"10.1016/j.ijrobp.2024.11.109","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Given the aggressive nature and poor prognosis of triple-negative breast cancer (TNBC), adjuvant capecitabine has been the standard therapy for residual disease after preoperative systemic therapy (PST). However, the optimal sequence of postoperative radiation therapy (RT) and capecitabine remains unclear. This study evaluated the efficacy and safety of concurrent RT and capecitabine (RT+CAP) versus sequential RT followed by capecitabine (RT→CAP) in patients with residual TNBC after PST.</p><p><strong>Materials and methods: </strong>In this multicenter retrospective study, data from 491 patients treated at 14 tertiary hospitals were analyzed. The patients received either postoperative RT→CAP (n=255) or RT+CAP (n=236). Survival outcomes were analyzed using the Kaplan-Meier method, and multivariable Cox regression was used to adjust for potential confounders.</p><p><strong>Results: </strong>There were no significant differences in the baseline characteristics between the two groups. With a median follow-up of 41.8 months, the 4-year rates of disease-free survival (DFS) and overall survival (OS) were 68.8% and 82.4%, respectively. The RT+CAP group demonstrated improvements in DFS (74.6% vs. 63.7%, p=0.045) and OS (86.8% vs. 78.3%, p=0.006) compared to the RT→CAP group. Specifically, RT+CAP showed superior DFS and OS outcomes in patients with a low disease burden (ypT0-1, ypN0/axillar level I only, or Ki67 <15%). Additionally, the incidence of ≥grade 2 toxicities and discontinuation of capecitabine due to toxicity did not differ, indicating that RT+CAP was well tolerated.</p><p><strong>Conclusions: </strong>RT+CAP offers improvements in oncologic outcomes without an increase in adverse events compared to RT→CAP, suggesting it is a promising treatment option for patients with residual TNBC after PST.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.4000,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Concurrent vs. Sequential Adjuvant Capecitabine-Based Chemoradiation in Residual TNBC after neoadjuvant-chemotherapy: A Multicenter comparative Study.\",\"authors\":\"Nalee Kim, Su Ssan Kim, Won Kyung Cho, Won Park, Ji Hyun Chang, Yong Bae Kim, Ah Ram Chang, Tae Hyun Kim, Jongmoo Park, Jin Hee Kim, Kyubo Kim, Yu Jin Lim, Tae Gyu Kim, Jin Hwa Choi, Jeanny Kwon, Sungmin Kim, Kyung Hwan Shin, Haeyoung Kim\",\"doi\":\"10.1016/j.ijrobp.2024.11.109\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Given the aggressive nature and poor prognosis of triple-negative breast cancer (TNBC), adjuvant capecitabine has been the standard therapy for residual disease after preoperative systemic therapy (PST). However, the optimal sequence of postoperative radiation therapy (RT) and capecitabine remains unclear. This study evaluated the efficacy and safety of concurrent RT and capecitabine (RT+CAP) versus sequential RT followed by capecitabine (RT→CAP) in patients with residual TNBC after PST.</p><p><strong>Materials and methods: </strong>In this multicenter retrospective study, data from 491 patients treated at 14 tertiary hospitals were analyzed. The patients received either postoperative RT→CAP (n=255) or RT+CAP (n=236). Survival outcomes were analyzed using the Kaplan-Meier method, and multivariable Cox regression was used to adjust for potential confounders.</p><p><strong>Results: </strong>There were no significant differences in the baseline characteristics between the two groups. With a median follow-up of 41.8 months, the 4-year rates of disease-free survival (DFS) and overall survival (OS) were 68.8% and 82.4%, respectively. The RT+CAP group demonstrated improvements in DFS (74.6% vs. 63.7%, p=0.045) and OS (86.8% vs. 78.3%, p=0.006) compared to the RT→CAP group. Specifically, RT+CAP showed superior DFS and OS outcomes in patients with a low disease burden (ypT0-1, ypN0/axillar level I only, or Ki67 <15%). Additionally, the incidence of ≥grade 2 toxicities and discontinuation of capecitabine due to toxicity did not differ, indicating that RT+CAP was well tolerated.</p><p><strong>Conclusions: </strong>RT+CAP offers improvements in oncologic outcomes without an increase in adverse events compared to RT→CAP, suggesting it is a promising treatment option for patients with residual TNBC after PST.</p>\",\"PeriodicalId\":14215,\"journal\":{\"name\":\"International Journal of Radiation Oncology Biology Physics\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":6.4000,\"publicationDate\":\"2024-12-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Radiation Oncology Biology Physics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ijrobp.2024.11.109\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijrobp.2024.11.109","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
Concurrent vs. Sequential Adjuvant Capecitabine-Based Chemoradiation in Residual TNBC after neoadjuvant-chemotherapy: A Multicenter comparative Study.

Purpose: Given the aggressive nature and poor prognosis of triple-negative breast cancer (TNBC), adjuvant capecitabine has been the standard therapy for residual disease after preoperative systemic therapy (PST). However, the optimal sequence of postoperative radiation therapy (RT) and capecitabine remains unclear. This study evaluated the efficacy and safety of concurrent RT and capecitabine (RT+CAP) versus sequential RT followed by capecitabine (RT→CAP) in patients with residual TNBC after PST.

Materials and methods: In this multicenter retrospective study, data from 491 patients treated at 14 tertiary hospitals were analyzed. The patients received either postoperative RT→CAP (n=255) or RT+CAP (n=236). Survival outcomes were analyzed using the Kaplan-Meier method, and multivariable Cox regression was used to adjust for potential confounders.

Results: There were no significant differences in the baseline characteristics between the two groups. With a median follow-up of 41.8 months, the 4-year rates of disease-free survival (DFS) and overall survival (OS) were 68.8% and 82.4%, respectively. The RT+CAP group demonstrated improvements in DFS (74.6% vs. 63.7%, p=0.045) and OS (86.8% vs. 78.3%, p=0.006) compared to the RT→CAP group. Specifically, RT+CAP showed superior DFS and OS outcomes in patients with a low disease burden (ypT0-1, ypN0/axillar level I only, or Ki67 <15%). Additionally, the incidence of ≥grade 2 toxicities and discontinuation of capecitabine due to toxicity did not differ, indicating that RT+CAP was well tolerated.

Conclusions: RT+CAP offers improvements in oncologic outcomes without an increase in adverse events compared to RT→CAP, suggesting it is a promising treatment option for patients with residual TNBC after PST.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
11.00
自引率
7.10%
发文量
2538
审稿时长
6.6 weeks
期刊介绍: International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field. This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信